Goldman Small Cap Research Issues Research Report on Itonis, Inc.
(firmenpresse) - BALTIMORE, MD -- (Marketwire) -- 11/07/12 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has issued research coverage of Itonis, Inc. (PINKSHEETS: ITNS), a holding company with divisions in key verticals, including pharmaceuticals, industrials, and technology.
The crown jewel in the Itonis family is Itonis Pharmaceuticals, which is developing what may be the first over-the-counter, systemically active preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea. The size of this market is an estimated $1 billion annually.
Itonis Pharmaceuticals is led by Dr. Charles Hensley, the famed homeopathic and nutraceutical pioneer and a founder of the Firm that launched the popular Zicam® Cold Remedy.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.
"Dr. Hensley's product development innovation and marketing savvy helped make Zicam® a household name and transformed how homeopathic drugs are marketed and sold in the U.S. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of anti-nausea, as well as other common ailments and chronic diseases, including HIV. Given the advantages of the anti-nausea offering and the leadership's history of success, Itonis Pharmaceuticals could be a major player in the homeopathic and nutraceutical arena."
To view a summary of the report or download the report in its entirety, please visit
Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit .
Itonis, Inc. (PINKSHEETS: ITNS) is a holding company for the recently formed Itonis Pharmaceuticals, Inc., Paramount Discoveries, Inc. and AppRocket. Led by Dr. Charles Hensley, the founder of the Firm that launched the popular Zicam® Cold Remedy, the pharmaceutical division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. For more information on Itonis, Inc. and its holdings, visit the Company's website at .
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.11.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 1168062
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BALTIMORE, MD
Phone:
Kategorie:
Commercial & Investment Banking
Anmerkungen:
Diese Pressemitteilung wurde bisher 155 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Goldman Small Cap Research Issues Research Report on Itonis, Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Goldman Small Cap Research (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
